The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer

被引:0
|
作者
Sanguedolce, R
Vultaggio, G
Sanguedolce, F
Modica, G
Volsi, FL
Diana, G
Guereio, G
Bellanca, L
Rausa, L
机构
[1] Policlin Palermo, Ist Farmacol, I-90127 Palermo, Italy
[2] Policlin Palermo, Ist Clin & Fisiopatol Chirurg, Palermo, Italy
[3] Policlin Palermo, Ist Clin Chirurg, Palermo, Italy
[4] Policlin Palermo, Ist Oncol, Palermo, Italy
[5] Policlin Palermo, CIROC, Palermo, Italy
关键词
thymidylate synthase; 5-fluorouracil; colorectal cancer;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inhibition of Thymidylate Synthase (TS) by the 5-Fluorouracil (5Fu) active metabolite Fluoro-deoxy-uridine-monophosphate (FdUMP) is considered to be the main mechanism of action of 5Fu. TS level from tumors and normal mucosa of 62 untreated patients who underwent surgery for primary colorectal adenocarcinoma was performed. The aim of this study was to evaluate the possibility of considering the TS level as a prognostic factor of the disease. A large variation in the level of the enzyme was found among tumors. Our data demonstrate that there is no association with age, sex, and tumor size; however there are significant relationships between TS levels and staging and histological grading, lit fact the TS values are higher in Dukes' A and in G1 than in Dukes' D and G3 tumors (p<0,05). Another significant association has been found between the TS level and tumor; site: pts with light colon neoplasias had higher TS levels than pts with left and rectum ones. An interesting trend was found between the TS levels and survival parameters. Pts who had lower TS levels had a significantly increased risk of death (p<0,05) over pts with a higher outcome. Our data support the hypothesis that a high TS level is a favourable prognostic factor in human untreated colorectal carcinomas according to our previous preliminary data (1).
引用
收藏
页码:1515 / 1520
页数:6
相关论文
共 50 条
  • [41] Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer
    Fernandez-Contreras, Maria-Encarnacion
    Javier Sanchez-Hernandez, Jose
    Guijarro, Mercedes
    Gisbert, Javier P.
    Rivas, Noa
    Garcia De Paredes, Maria-Luisa
    Hinojar-Gutierrez, Adolfo
    Gamallo, Carlos
    ONCOLOGY REPORTS, 2010, 23 (05) : 1393 - 1400
  • [42] Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients
    Sharma, Rohini
    Hoskins, Janelle M.
    Rivory, Laurent P.
    Zucknick, Manuela
    London, Rosyln
    Liddle, Christopher
    Clarke, Stephen J.
    CLINICAL CANCER RESEARCH, 2008, 14 (03) : 817 - 825
  • [43] Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer
    Nishimura, R
    Nagao, K
    Miyayama, H
    Matsuda, M
    Baba, K
    Matsuoka, Y
    Yamashita, H
    Fukuda, M
    Higuchi, A
    Satoh, A
    Mizumoto, T
    Hamamoto, R
    ANTICANCER RESEARCH, 1999, 19 (6C) : 5621 - 5626
  • [44] Reply: Thymidylate synthase polymorphism and survival of colorectal cancer patients treated with 5-fluorouracil
    Iacopetta, B
    Elsaleh, H
    BRITISH JOURNAL OF CANCER, 2002, 86 (08) : 1366 - 1366
  • [45] ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy
    Shirota, Y
    Stoehlmacher, J
    Brabender, J
    Xiang, YP
    Uetake, H
    Danenberg, KD
    Groshen, S
    Tsao-Wei, DD
    Danenberg, PV
    Lenz, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (23) : 4298 - 4304
  • [46] Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels:: Predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil
    Kornmann, M
    Schwabe, W
    Sander, S
    Kron, M
    Sträter, J
    Polat, S
    Kettner, E
    Weiser, HF
    Baumann, W
    Schramm, H
    Häusler, P
    Ott, K
    Behnke, D
    Staib, L
    Beger, HG
    Link, KH
    CLINICAL CANCER RESEARCH, 2003, 9 (11) : 4116 - 4124
  • [47] Role of topoisomerase I and thymidylate synthase expression in sporadic colorectal cancer: Associations with clinicopathological and molecular features
    Azzoni, Cinzia
    Bottarelli, Lorena
    Cecchini, Stefano
    Ziccarelli, Antonio
    Campanini, Nicoletta
    Bordi, Cesare
    Sarli, Leopoldo
    Silini, Enrico Maria
    PATHOLOGY RESEARCH AND PRACTICE, 2014, 210 (02) : 111 - 117
  • [48] Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed
    Avallone, Antonio
    Di Gennaro, Elena
    Silvestro, Lucrezia
    Iaffaioli, Vincenzo Rosario
    Budillon, Alfredo
    EXPERT OPINION ON DRUG SAFETY, 2014, 13 (01) : 113 - 129
  • [49] Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer
    Corsi, DC
    Ciaparrone, M
    Zannoni, G
    Mancini, M
    Cassano, A
    Specchia, M
    Pozzo, C
    Martini, M
    Barone, C
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (04) : 527 - 534
  • [50] Microsatellite instability and the association with plasma homocysteine and thymidylate synthase in colorectal cancer
    Jensen, Lars Henrik
    Lindebjerg, Jan
    Cruger, Dorthe Gylling
    Brandslund, Ivan
    Jakobsen, Anders
    Kolvraa, Steen
    Nielsen, Jens Nederby
    CANCER INVESTIGATION, 2008, 26 (06) : 583 - 589